# Colitis, Ulcerative FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/colitis-ulcerative

> 8 upcoming FDA catalysts in colitis, Ulcerative: guselkumab subcutaneous (JNJ) on Feb to May 2027 (topline data readout); guselkumab subcutaneous (JNJ) on February 2027 (primary completion); ICOTYDE (icotrokinra, JNJ) on Jan to Apr 2028 (topline data readout); ICOTYDE (icotrokinra, JNJ) on January 2028 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 8, 2025 | [Ustekinumab dose based on bsa and body weight primary completion](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) | JNJ | Colitis, Ulcerative | completed | "NCT04630028 (A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-10-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04630028)) |
| May 15, 2025 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Colitis, Ulcerative | completed | "NCT05242484 (A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05242484)) |
| July 1, 2025 | [Entyvio® (vedolizumab) primary completion](https://sec-api.dev/pdufa/vedolizumab) | TAK | Colitis, Ulcerative | completed | "NCT04779307 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-01 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-04-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04779307)) |
| September 30, 2025 | [Zeposia (ozanimod hydrochloride) primary completion](https://sec-api.dev/pdufa/ozanimod) | BMY | Colitis, Ulcerative | completed | "NCT03915769 (To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03915769)) |
| February 10, 2026 | [SAR443122 primary completion](https://sec-api.dev/pdufa/sar443122) | SNY | Colitis Ulcerative | completed | "NCT05588843 (Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05588843)) |
| April 30, 2026 | [Entyvio® (vedolizumab) topline data readout](https://sec-api.dev/pdufa/vedolizumab) | TAK | Colitis, Ulcerative | completed | "NCT04779307 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-01 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-04-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04779307?tab=results)) |
| May 13, 2026 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Colitis Ulcerative | completed | "NCT05731128 (A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-13 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05731128)) |
| August 6, 2026 | [SAR441566 primary completion](https://sec-api.dev/pdufa/sar441566) | SNY | Colitis Ulcerative | withdrawn | "NCT06867094 (A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-08-06 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06867094)) |
| October 20, 2026 | [Ustekinumab dose based on bsa and body weight topline data readout](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) | JNJ | Colitis, Ulcerative | completed | "NCT04630028 (A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-10-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04630028?tab=results)) |
| Feb to May 2027 | [Guselkumab subcutaneous topline data readout](https://sec-api.dev/pdufa/guselkumab-subcutaneous) | JNJ | Colitis, Ulcerative | scheduled | "NCT06260163 (A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260163)) |
| February 2027 | [Guselkumab subcutaneous primary completion](https://sec-api.dev/pdufa/guselkumab-subcutaneous) | JNJ | Colitis, Ulcerative | scheduled | "NCT06260163 (A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06260163)) |
| Jan to Apr 2028 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Colitis, Ulcerative | scheduled | "NCT07196748 (A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196748)) |
| January 2028 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Colitis, Ulcerative | scheduled | "NCT07196748 (A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196748)) |
| Aug to Nov 2028 | [Tremfya (guselkumab) topline data readout](https://sec-api.dev/pdufa/guselkumab) | JNJ | Colitis, Ulcerative | scheduled | "NCT07577856 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07577856)) |
| August 2028 | [Tremfya (guselkumab) primary completion](https://sec-api.dev/pdufa/guselkumab) | JNJ | Colitis, Ulcerative | scheduled | "NCT07577856 (A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-11 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07577856)) |
| Sep to Dec 2030 | [Etrasimod topline data readout](https://sec-api.dev/pdufa/etrasimod) | PFE | Colitis, Ulcerative | scheduled | "NCT07470879 (A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-09-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07470879)) |
| September 2030 | [Etrasimod primary completion](https://sec-api.dev/pdufa/etrasimod) | PFE | Colitis, Ulcerative | scheduled | "NCT07470879 (A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-09-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07470879)) |

## Drugs

- [Ustekinumab dose based on bsa and body weight](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) (JNJ)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Zeposia (ozanimod hydrochloride)](https://sec-api.dev/pdufa/ozanimod) (BMY)
- [SAR443122](https://sec-api.dev/pdufa/sar443122) (SNY)
- [Dupixent (dupilumab)](https://sec-api.dev/pdufa/dupilumab) (REGN)
- [SAR441566](https://sec-api.dev/pdufa/sar441566) (SNY)
- [Guselkumab subcutaneous](https://sec-api.dev/pdufa/guselkumab-subcutaneous) (JNJ)
- [ICOTYDE (icotrokinra)](https://sec-api.dev/pdufa/icotrokinra) (JNJ)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/colitis-ulcerative.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Colitis, Ulcerative FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/colitis-ulcerative

```bibtex
@misc{secapidev_indications_colitis_ulcerative_20261116,
  title        = {Colitis, Ulcerative FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/colitis-ulcerative}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_colitis_ulcerative_20261116","title":"Colitis, Ulcerative FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/colitis-ulcerative","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
